BioPharmX starts phase 2 clinical study under US FDA IND for BPX-01
The company will evaluate effectiveness in decreasing the number of acne-causing bacteria in patients at four weeks and assess the drug’s safety and tolerability. It is the first
Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium-based provider of development and manufacturing services for liquid and semi-solid dosage forms in the pharmaceutical sector.
The ARRIVE Study is a randomized, double-blinded, allocation-concealed, placebo-controlled, proof-of-concept Phase IIa clinical trial, which is an investigator-initiated study, and is being conducted at the NAFLD Research Center,